Estrella Immunopharma opened higher at $0.80, compared with its previous close of $0.79. In the last trading session, the stock traded between $0.40 and $0.80. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Estrella Immunopharma is now worth
$ 14.70
Resulting in a loss of
$ 85.30 (85.30%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.28 (-35.76%)
Day High
$0.80
Day Low
$0.40
Day Open
$0.80
Prev Close
$0.79
Volume
15,67,257
1W Return
17.24%
1M Return
54.55%
3M Return
-29.56%
6M Return
-59.52%
1Y Return
-79.68%
Fundamentals
Market Cap ($ Mn)
22
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
233.39%
EPS (TTM)
$-0.05
Investment Returns
1 Week
17.24%
1 Month
54.55%
3 Months
-29.56%
6 Months
-59.52%
9 Months
-60.77%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
16Oct
Estrella Immunopharma reports no SAEs in first EB103 dose-expansion patient
First patient in dose-expansion phase received two EB103 infusions three weeks apart. No treatment-related serious adverse events observed during the first month of follow-up. Doses administered at recommended Phase II dose of 5 × 10⁶ EB103 T cells/kg. Dose-escalation phase previously showed 100% complete response rate at Month 1.
27 days ago
3Aug
Estrella Immunopharma activates third site for EB103 NHL trial
Estrella Immunopharma has expanded its STARLIGHT-1 Phase I/II trial for EB103 by activating a third clinical site at Oregon Health & Science University. This move aims to accelerate enrollment and data collection for the CD19-Redirected ARTEMIS T-cell therapy targeting relapsed or refractory B-cell non-Hodgkin’s lymphoma.
3mo ago
9Jul
Abbott Cooper investigates Estrella Immunopharma board
Abbott Cooper PLLC has launched an investigation into potential legal claims against Estrella Immunopharma, Inc.'s board for possible fiduciary violations. The firm is representing stockholders and operates on a contingency fee basis. Estrella's common stock trades on Nasdaq under the ticker "ESLA.".
